Shanghai Stonedrop Investment Management Center

Shanghai Stonedrop Investment Management Center appears to be a Shanghai-based investment management entity organized as a limited partnership rather than a drug developer, healthcare operator, or life sciences company. Publicly available evidence links it to an April 2022 investment agreement to invest up to $15 million in AnPac Bio-Medical Science, where it was referred to as "Shanghai Stonedrop." Related SEC disclosure also identifies a closely associated entity, Stonedrop Investment Management (Shanghai) Co., Ltd., as an early investor and Chinese strategic investment firm. Based on the available information, the entity functions as an investment vehicle or fund rather than an operating biotech or pharma company. No evidence was found of an internal therapeutic pipeline, proprietary drug programs, or clinical-stage assets.